Volume 79, Issue 10, Pages (May 2011)

Slides:



Advertisements
Similar presentations
Volume 70, Issue 1, Pages (July 2006)
Advertisements

Volume 67, Issue 2, Pages (February 2005)
Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury  Marisa D. Covington,
Volume 66, Issue 1, Pages (July 2004)
Inflammatory cytokines in acute renal failure
Lymphatic vessels develop during tubulointerstitial fibrosis
Volume 63, Issue 6, Pages (June 2003)
Volume 77, Issue 10, Pages (May 2010)
Volume 78, Issue 3, Pages (August 2010)
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Volume 82, Issue 6, Pages (September 2012)
Volume 91, Issue 2, Pages (February 2017)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Volume 69, Issue 8, Pages (April 2006)
Volume 82, Issue 8, Pages (October 2012)
Volume 79, Issue 6, Pages (March 2011)
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy  J.-A. Moon,
Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury  Marisa D. Covington,
Volume 83, Issue 5, Pages (May 2013)
Volume 61, Issue 5, Pages (May 2002)
Volume 88, Issue 3, Pages (September 2015)
Volume 84, Issue 5, Pages (November 2013)
Volume 75, Issue 2, Pages (January 2009)
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Mechanisms of the proteinuria induced by Rho GTPases
Volume 67, Issue 4, Pages (April 2005)
Volume 63, Issue 6, Pages (June 2003)
Volume 75, Issue 11, Pages (June 2009)
Volume 64, Issue 5, Pages (November 2003)
Volume 85, Issue 4, Pages (April 2014)
Volume 87, Issue 2, Pages (February 2015)
Volume 81, Issue 3, Pages (February 2012)
Volume 65, Issue 6, Pages (June 2004)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
Volume 79, Issue 1, Pages (January 2011)
Volume 73, Issue 4, Pages (February 2008)
Volume 80, Issue 12, Pages (December 2011)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Volume 70, Issue 1, Pages (July 2006)
Volume 75, Issue 7, Pages (April 2009)
Volume 67, Issue 2, Pages (February 2005)
Volume 62, Issue 2, Pages (August 2002)
Renoprotective role of the vitamin D receptor in diabetic nephropathy
Volume 78, Issue 6, Pages (September 2010)
Lymphatic vessels develop during tubulointerstitial fibrosis
Volume 80, Issue 10, Pages (November 2011)
Volume 86, Issue 4, Pages (October 2014)
Volume 73, Issue 1, Pages (January 2008)
Volume 79, Issue 4, Pages (February 2011)
Jin H. Li, Xiao R. Huang, Hong-Jian Zhu, Richard Johnson, Hui Y. Lan 
Volume 68, Issue 1, Pages (July 2005)
Volume 76, Issue 5, Pages (September 2009)
Genetic deficiency of adiponectin protects against acute kidney injury
Volume 63, Issue 2, Pages (February 2003)
Volume 66, Issue 1, Pages (July 2004)
Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity  Fuad S. Shihab, Hong Yi, William M. Bennett, Takeshi.
Volume 67, Issue 2, Pages (February 2005)
Volume 76, Issue 7, Pages (October 2009)
Volume 68, Issue 2, Pages (August 2005)
Volume 82, Issue 3, Pages (August 2012)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 74, Issue 1, Pages (July 2008)
LncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy  Juan Wang, Jian Pang, Huiling Li, Jie Long, Fang Fang, Junxiang Chen,
Volume 69, Issue 11, Pages (June 2006)
Volume 85, Issue 1, Pages (January 2014)
Volume 76, Issue 8, Pages (October 2009)
Volume 73, Issue 9, Pages (May 2008)
Volume 56, Issue 6, Pages (December 1999)
Volume 65, Issue 6, Pages (June 2004)
Volume 65, Issue 6, Pages (June 2004)
Presentation transcript:

Volume 79, Issue 10, Pages 1090-1098 (May 2011) Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes  Alaa S. Awad, Michael D. Rouse, Konstantine Khutsishvili, Liping Huang, W. Kline Bolton, Kevin R. Lynch, Mark D. Okusa  Kidney International  Volume 79, Issue 10, Pages 1090-1098 (May 2011) DOI: 10.1038/ki.2010.544 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 FTY720 and SEW2871 reduce urinary albumin excretion in diabetic rats. To determine the effect of FTY720 and SEW2871 in diabetic rats, 24-h urine collections were obtained for measurement of urine albumin at baseline (W0) and at weeks (W) 3, 6, and 9 of the study. Open bars, control group; black bars, vehicle-treated diabetes group; dark gray bars, diabetes group treated with FTY720 (0.3mg/kg, oral gavage); and light gray bars, diabetes group treated with SEW2871 (0.1mg/kg, i.p.). Data are means±s.e.m. *P<0.05, **P<0.005 and ***P<0.0005 compared with control; +P<0.05, ++P<0.01 and +++P<0.005 compared with vehicle-treated diabetes group. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 FTY720 and SEW2871 improve renal histology in diabetic nephropathy. Masson's trichrome staining of kidney sections from normal control rat (a, e), diabetic rat treated with vehicle (b, f), and a diabetic rat treated with FTY720 (c, g) or SEW2871 (d, h) at 9 weeks of the study. Representative photographs show extensive tubular damage with vacuolization (arrows), interstitial fibrosis (blue staining of interstitial collagen), and increased intertubular space (arrowhead) in vehicle-treated diabetic rats and minimal changes in treated animals. Bar=50μm. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 FTY720 and SEW2871 reduce urinary tumor necrosis factor-α (TNF-α) level. Urine collections (24-h) were obtained for measurement of TNF-α in rats after 9 weeks of streptozotocin (STZ)-induced diabetes. Open bar, control group; filled bar, vehicle-treated diabetes group; hatched bar, diabetes group treated with FTY720 (0.3mg/kg, oral gavage); and gray bar, diabetes group treated with SEW2871 (0.1mg/kg, i.p.). Values are means±s.e.m. *P<0.05, **P<0.01, and ***P<0.005 compared with control; +P<0.05 and ++P<0.01 compared with vehicle-treated diabetes group. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 SEW2871 reduces urinary albumin excretion (UAE) in Rag-1 diabetic mice. Urine collections were obtained for measurement of UAE at week 6 in wild-type (WT) and Rag-1 mice after streptozotocin (STZ)-induced diabetes. Open bars, control group; black bars, vehicle-treated diabetes group; and gray bars, diabetes group treated with SEW2871 (1mg/kg, i.p.). Data are means±s.e.m. *P<0.05 and **P<0.01 compared with control; +P<0.05 compared with vehicle-treated diabetes group. Blood glucose (BG) values are shown below the bars for each group. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 FTY720 reduces albuminuria independent of sphingosine 1-phosphate 3 receptor (S1P3R) effects. Urine collections were obtained for measurement of urinary albumin excretion (UAE) at week 4 in S1P3+/+ (wild type, WT) and S1P3−/− mice after streptozotocin (STZ)-induced diabetes. Open bars, control group; black bars, vehicle-treated diabetes group; and gray bar, diabetes group treated with FTY720 (0.3mg/kg, oral gavage). Data are means±s.e.m. *P<0.05 compared with control; +P<0.05 compared with vehicle-treated diabetes group. Blood glucose (BG) values are shown below the bars for each group. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 6 Sphingosine 1-phosphate 1 receptor (S1P1R) agonists regulate podocyte-specific proteins. (a, b) Reverse transcriptase-PCR (RT-PCR) was performed on whole rat kidney total RNA isolated after 9 weeks of diabetes from control, vehicle-treated diabetic (D) rats, and diabetic rats treated with FTY720 or SEW2871. (a) Gel analysis of PCR products. (b) Expression of nephrin and podocin mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and data were calculated as expression relative to control. Black bars, vehicle-treated diabetic rats; dark gray bars, diabetic rats treated with FTY720 (0.3mg/kg, oral gavage); and light gray bars, diabetic rats treated with SEW2871 (0.1mg/kg, i.p.). Data are means±s.e.m. *P<0.05, **P<0.005 compared with control (dashed line); +P<0.05, ++P<0.01 compared with vehicle-treated diabetes group. (c–f) WT-1 staining of rat kidney after 9 weeks of diabetes from control (c), vehicle-treated diabetic (d) rats, and diabetic rats treated with FTY720 (e) or SEW2871 (f) (magnification × 400). Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 7 Role of sphingosine 1-phosphate 1 receptor (S1P1R) agonists in immortalized podocytes in vitro. (a, b) Total RNA from immortalized podocytes was extracted and subjected to analysis by reverse transcriptase-PCR (RT-PCR) for S1P receptor mRNA expression (a) and sphingosine kinase 1 and 2 (SphK1 and SphK2) mRNA expression (b). (c, d) Total RNA from immortalized podocytes subjected to normal glucose (NG) or high glucose (HG) media for 14 days with or without SEW2871 (n=5–6 each group) was extracted and subjected to analysis by RT-PCR for tumor necrosis factor-α (TNF-α) mRNA expression (c) and vascular endothelial growth factor (VEGF) mRNA expression (d). Expression of TNF-α and VEGF mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Open bars, NG; black bars, HG treated with vehicle; and gray bars, HG treated with SEW2871 (1μmol/l). Data are means±s.e.m. *P<0.05, **P<0.01 compared with NG; +P<0.05 compared with HG + vehicle. Kidney International 2011 79, 1090-1098DOI: (10.1038/ki.2010.544) Copyright © 2011 International Society of Nephrology Terms and Conditions